Astrocytoma – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 7 PAGES: 204

More Info
									                        Astrocytoma – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1928IDB
                                                                                              Publication Date: April 2012




Astrocytoma – Pipeline Review, H1 2012                                                        GMDHC1928IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Astrocytoma – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 7
    List of Figures .............................................................................................................................................................................. 10
Introduction....................................................................................................................................................................................... 11
    Global Markets Direct Report Coverage ...................................................................................................................................... 11
Astrocytoma Overview...................................................................................................................................................................... 12
Therapeutics Development............................................................................................................................................................... 13
    An Overview of Pipeline Products for Astrocytoma ..................................................................................................................... 13
Astrocytoma Therapeutics under Development by Companies ........................................................................................................ 15
Astrocytoma Therapeutics under Investigation by Universities/Institutes ......................................................................................... 21
Late Stage Products ......................................................................................................................................................................... 29
    Comparative Analysis .................................................................................................................................................................. 29
Mid Clinical Stage Products.............................................................................................................................................................. 30
    Comparative Analysis .................................................................................................................................................................. 30
Early Clinical Stage Products ........................................................................................................................................................... 31
    Comparative Analysis .................................................................................................................................................................. 31
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 32
    Comparative Analysis .................................................................................................................................................................. 32
Astrocytoma Therapeutics – Products under Development by Companies ...................................................................................... 33
Astrocytoma Therapeutics – Products under Investigation by Universities/Institutes ....................................................................... 39
Companies Involved in Astrocytoma Therapeutics Development..................................................................................................... 56
    Boehringer Ingelheim GmbH ....................................................................................................................................................... 56
    F. Hoffmann-La Roche Ltd. ......................................................................................................................................................... 57
    Amgen Inc. .................................................................................................................................................................................. 58
    Sanofi-Aventis ............................................................................................................................................................................. 59
    AstraZeneca PLC ........................................................................................................................................................................ 60
    Eli Lilly and Company .................................................................................................................................................................. 61
    Genentech, Inc. ........................................................................................................................................................................... 62
    Merck & Co., Inc. ......................................................................................................................................................................... 63
    Lentigen Corporation ................................................................................................................................................................... 64
    Sangamo BioSciences, Inc. ......................................................................................................................................................... 65
    Plexxikon Inc. .............................................................................................................................................................................. 66
    YM BioSciences Inc..................................................................................................................................................................... 67
    Celltrion, Inc................................................................................................................................................................................. 68
    Ark Therapeutics Group plc ......................................................................................................................................................... 69
    Millennium Pharmaceuticals, Inc. ................................................................................................................................................ 70
    Novartis AG ................................................................................................................................................................................. 71
    ImClone Systems Incorporated ................................................................................................................................................... 72
    Actelion Ltd .................................................................................................................................................................................. 73
    Eisai Co., Ltd. .............................................................................................................................................................................. 74
    Nippon Shinyaku Co., Ltd. ........................................................................................................................................................... 75
    OSI Pharmaceuticals, Inc. ........................................................................................................................................................... 76



Astrocytoma – Pipeline Review, H1 2012                                                                                                            GMDHC1928IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(2)
Astrocytoma – Pipeline Review, H1 2012




    Pfizer Inc...................................................................................................................................................................................... 77
    Cell Therapeutics, Inc. ................................................................................................................................................................. 78
    Exelixis, Inc.................................................................................................................................................................................. 79
    Aduro BioTech ............................................................................................................................................................................. 80
    Merck KGaA ................................................................................................................................................................................ 81
    Celldex Therapeutics, Inc. ........................................................................................................................................................... 82
    ImmunoCellular Therapeutics, Ltd. .............................................................................................................................................. 83
    Lixte Biotechnology Holdings, Inc. ............................................................................................................................................... 84
    Northwest Biotherapeutics, Inc. ................................................................................................................................................... 85
    Oncothyreon Inc .......................................................................................................................................................................... 86
    Peregrine Pharmaceuticals, Inc. .................................................................................................................................................. 87
    Pharmacyclics, Inc....................................................................................................................................................................... 88
    Threshold Pharmaceuticals, Inc. ................................................................................................................................................. 89
    Proximagen Neuroscience plc. .................................................................................................................................................... 90
    Protox Therapeutics Inc............................................................................................................................................................... 91
    Rexahn Pharmaceuticals, Inc. ..................................................................................................................................................... 92
    Antisense Pharma GmbH ............................................................................................................................................................ 93
    INSYS Therapeutics, Inc. ............................................................................................................................................................ 94
    Ambit Biosciences Corporation.................................................................................................................................................... 95
    Immupharma Plc ......................................................................................................................................................................... 96
    Adnexus Therapeutics, Inc. ......................................................................................................................................................... 97
    immatics biotechnologies GmbH ................................................................................................................................................. 98
    Apogenix GmbH .......................................................................................................................................................................... 99
    Indena S.p.A. ............................................................................................................................................................................. 100
    Diffusion Pharmaceuticals LLC.................................................................................................................................................. 101
    Arno Therapeutics, Inc. ............................................................................................................................................................. 102
    Nobelpharma Co., Ltd. .............................................................................................................................................................. 103
    Vascular Biogenics Ltd. ............................................................................................................................................................. 104
    BioCancell Therapeutics, Inc. .................................................................................................................................................... 105
    Axelar AB................................................................................................................................................................................... 106
    Advenchen Laboratories, LLC ................................................................................................................................................... 107
    Myriad Pharmaceuticals, Inc...................................................................................................................................................... 108
    NOXXON Pharma AG ............................................................................................................................................................... 109
    ChemoCentryx, Inc. ................................................................................................................................................................... 110
    TVAX Biomedical, LLC .............................................................................................................................................................. 111
    Sirnaomics, Inc. ......................................................................................................................................................................... 112
    Nexgenix Pharmaceuticals, LLC................................................................................................................................................ 113
    Archer Biosciences, Inc ............................................................................................................................................................. 114
    Lipocine Inc. .............................................................................................................................................................................. 115
    R&D Systems, Inc. .................................................................................................................................................................... 116
    TAU Therapeutics, LLC ............................................................................................................................................................. 117
    Tocagen Inc ............................................................................................................................................................................... 118
    CytomX, LLC. ............................................................................................................................................................................ 119
Astrocytoma – Therapeutics Assessment ...................................................................................................................................... 120


Astrocytoma – Pipeline Review, H1 2012                                                                                                             GMDHC1928IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(3)
Astrocytoma – Pipeline Review, H1 2012




    Assessment by Monotherapy Products ..................................................................................................................................... 120
    Assessment by Combination Products ...................................................................................................................................... 121
    Assessment by Route of Administration .................................................................................................................................... 122
    Assessment by Molecule Type .................................................................................................................................................. 125
Drug Profiles................................................................................................................................................................................... 128
    Enzastaurin - Drug Profile ......................................................................................................................................................... 128
        Product Description............................................................................................................................................................... 128
        Mechanism of Action ............................................................................................................................................................. 128
        R&D Progress ....................................................................................................................................................................... 128
    Recentin - Drug Profile .............................................................................................................................................................. 130
        Product Description............................................................................................................................................................... 130
        Mechanism of Action ............................................................................................................................................................. 130
        R&D Progress ....................................................................................................................................................................... 130
    Rindopepimut - Drug Profile ...................................................................................................................................................... 132
        Product Description............................................................................................................................................................... 132
        Mechanism of Action ............................................................................................................................................................. 132
        R&D Progress ....................................................................................................................................................................... 132
    Avastin - Drug Profile................................................................................................................................................................. 133
        Product Description............................................................................................................................................................... 133
        Mechanism of Action ............................................................................................................................................................. 133
        R&D Progress ....................................................................................................................................................................... 133
    Cilengitide - Drug Profile ............................................................................................................................................................ 135
        Product Description............................................................................................................................................................... 135
        Mechanism of Action ............................................................................................................................................................. 135
        R&D Progress ....................................................................................................................................................................... 135
    IL13-PE38QQR - Drug Profile ................................................................................................................................................... 137
        Product Description............................................................................................................................................................... 137
        Mechanism of Action ............................................................................................................................................................. 137
        R&D Progress ....................................................................................................................................................................... 137
    Trabedersen - Drug Profile ........................................................................................................................................................ 139
        Product Description............................................................................................................................................................... 139
        Mechanism of Action ............................................................................................................................................................. 139
        R&D Progress ....................................................................................................................................................................... 139
    Cerepro - Drug Profile ............................................................................................................................................................... 141
        Product Description............................................................................................................................................................... 141
        Mechanism of Action ............................................................................................................................................................. 141
        R&D Progress ....................................................................................................................................................................... 141
    Recentin + Lomustine - Drug Profile .......................................................................................................................................... 143
        Product Description............................................................................................................................................................... 143
        Mechanism of Action ............................................................................................................................................................. 143
        R&D Progress ....................................................................................................................................................................... 143
    Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Methotrexate + Temozolomide + Thiotepa + Vincristine + Stem cell
    transplantation + Radiation Therapy - Drug Profile .................................................................................................................... 144
        Product Description............................................................................................................................................................... 144



Astrocytoma – Pipeline Review, H1 2012                                                                                                           GMDHC1928IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                 Page(4)
Astrocytoma – Pipeline Review, H1 2012




        Mechanism of Action ............................................................................................................................................................. 144
        R&D Progress ....................................................................................................................................................................... 145
    Temozolomide + Radiation Therapy - Drug Profile .................................................................................................................... 147
        Product Description............................................................................................................................................................... 147
        Mechanism of Action ............................................................................................................................................................. 147
        R&D Progress ....................................................................................................................................................................... 147
    Cilengitide + Temozolomide + Radiotherapy - Drug Profile ....................................................................................................... 149
        Product Description............................................................................................................................................................... 149
        Mechanism of Action ............................................................................................................................................................. 149
        R&D Progress ....................................................................................................................................................................... 149
    Avast
								
To top